Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438090 | 0.87 | CNR1 (0.59) | CNR1 | |
| SCHEMBL7645975 | 0.85 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL27641178 | 0.85 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL8110427 | 0.85 | CNR1 (0.56) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL8113790 | 0.83 | CNR1 (0.54) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL30583839 | 0.83 | EPHX2 (0.55) | CNR1 | |
| SCHEMBL31438085 | 0.83 | EPHX2 (0.55) | CNR1 | |
| SCHEMBL31438096 | 0.83 | EPHX2 (0.55) | CNR1 | |
| SCHEMBL31438086 | 0.83 | EPHX2 (0.55) | CNR1 | |
| SCHEMBL15364768 | 0.83 | CNR1 (0.76) | CNR1ALDH1A1MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494673-B1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RES TRIANGLE INST (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7285687-B2 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-10-23 | — | — | US | disclosed |
| US-7179800-B2 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1494673-A4 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RES TRIANGLE INST (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050159449-A1 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1494673-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6825209-B2 | AN AMIDE DERIVATIVE USED AS CANNABINOID ANTAGONIST FOR THE TREATMENT OF OBESITY, SCHIZOPHRENIA, MEMORY DYSFUNCTION AND MARIJUANA ABUSE | RESEARCH TRIANGLE INSTITUTE | 2004-11-30 | — | — | US | disclosed |
| WO-2003091189-A1 | CANNABINOIDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003088968-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030199536-A1 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199536-A1 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use | CNR1, CNR2, GPR18 | CNR1 1/4885ALDH1A1 3141/4885MEN1 4450/4885 |
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | CNR1, CNR2, HRH4 | CNR1 1/4885ALDH1A1 3786/4885MEN1 770/4885 |
| US-20050159449-A1 | Cannabinoids | CNR1, CNR2, OPRL1 | CNR1 1/4885ALDH1A1 3865/4885MEN1 2722/4885 |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | CNR1, CNR2, HRH4 | CNR1 1/4885ALDH1A1 3786/4885MEN1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.